BioPharmSignal logoBioPharmSignal

Biotech News

TherapeuticsMD Announces Third Quarter 2023 Financial Results

TherapeuticsMD (TXMD)TherapeuticsMDEarnings

Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives BOCA RATON, Fla. --(BUSINESS WIRE)--Nov. 14, 2023-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical

Related news

TXMDTherapeuticsMD2025-11-12 21:05 EST

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TXMDTherapeuticsMD2024-11-12 21:05 EST

TherapeuticsMD Announces Third Quarter 2024 Financial Results

DAREDare Bioscience, Inc.2019-11-07 13:30 EST

Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast

SERASera Prognostics2026-07-29 20:05 EST

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

FEMYFEMASYS2025-11-14 21:01 EST

Femasys Announces Third Quarter Financial Results for 2025

DAREDare Bioscience, Inc.2019-11-14 13:00 EST

Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

COOThe Cooper Companies2025-08-27 20:15 EST

CooperCompanies Announces Third Quarter 2025 Results

PGNYProgyny2026-07-23 19:30 EST

Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report

FEMYFEMASYS2026-05-08 20:05 EST

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

SERASera Prognostics2026-05-06 20:05 EST

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

View all latest news

TherapeuticsMD

Pharmaceutical Royalty Company TherapeuticsMD owns rights to royalties and license revenue from women’s health pharmaceutical products rather than operating a broad internal commercial organization. Royalty Portfolio Model Revenue is primarily tied to products licensed under the Mayne agreement, giving TherapeuticsMD exposure to partner...

Recent company news

TXMDTherapeuticsMD2026-05-12 20:05 EST

TherapeuticsMD Announces First Quarter 2026 Financial Results

TXMDTherapeuticsMD2026-03-30 20:05 EST

TherapeuticsMD Announces Full Year 2025 Financial Results

TXMDTherapeuticsMD2025-11-12 21:05 EST

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TXMDTherapeuticsMD2025-08-12 20:05 EST

TherapeuticsMD Announces Second Quarter 2025 Financial Results

TXMDTherapeuticsMD2025-05-13 20:05 EST

TherapeuticsMD Announces First Quarter 2025 Financial Results

Stock data

Close
2.09 USD
Market cap
23.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States